Biohaven Pharmaceutical (BHVN) PT Set at $57.00 by Cantor Fitzgerald

Biohaven Pharmaceutical (NYSE:BHVN) received a $57.00 target price from Cantor Fitzgerald in a report released on Wednesday, September 12th. The firm presently has a “buy” rating on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 57.20% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. Piper Jaffray Companies set a $48.00 target price on Biohaven Pharmaceutical and gave the stock a “buy” rating in a report on Thursday, August 16th. ValuEngine raised Biohaven Pharmaceutical from a “hold” rating to a “buy” rating in a report on Friday, June 1st. Canaccord Genuity reiterated a “buy” rating and issued a $40.00 price target on shares of Biohaven Pharmaceutical in a research report on Monday, June 11th. Zacks Investment Research lowered Biohaven Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 17th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $48.00 price target on shares of Biohaven Pharmaceutical in a research report on Friday, August 17th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $47.29.

NYSE:BHVN traded down $0.14 on Wednesday, reaching $36.26. 266,600 shares of the company’s stock traded hands, compared to its average volume of 494,214. The stock has a market cap of $1.51 billion, a PE ratio of -7.26 and a beta of 1.47. Biohaven Pharmaceutical has a 12 month low of $16.50 and a 12 month high of $44.28.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings results on Tuesday, August 14th. The company reported ($1.01) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.68) by $0.67. As a group, research analysts forecast that Biohaven Pharmaceutical will post -5.41 EPS for the current year.

Several large investors have recently made changes to their positions in the business. United Services Automobile Association boosted its position in shares of Biohaven Pharmaceutical by 20.1% during the second quarter. United Services Automobile Association now owns 16,420 shares of the company’s stock valued at $649,000 after buying an additional 2,743 shares during the period. Northern Trust Corp boosted its position in shares of Biohaven Pharmaceutical by 6.6% during the second quarter. Northern Trust Corp now owns 323,923 shares of the company’s stock valued at $12,802,000 after buying an additional 20,093 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Biohaven Pharmaceutical by 16.8% during the second quarter. Bank of New York Mellon Corp now owns 141,762 shares of the company’s stock valued at $5,603,000 after buying an additional 20,364 shares during the period. Jane Street Group LLC boosted its position in shares of Biohaven Pharmaceutical by 34.9% during the second quarter. Jane Street Group LLC now owns 16,884 shares of the company’s stock valued at $667,000 after buying an additional 4,365 shares during the period. Finally, California Public Employees Retirement System purchased a new position in shares of Biohaven Pharmaceutical during the second quarter valued at approximately $790,000. Institutional investors and hedge funds own 80.85% of the company’s stock.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.

Further Reading: How to Invest in Marijuana Stocks

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply